ArticleMolecular diversity2026
Rational in silico design of PPARγ agonists for type 2 diabetes: an integrated study using pharmacophore modeling, 3D-QSAR, molecular docking, MD simulations, DFT, and toxicity prediction.
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The rising incidence of type 2 diabetes mellitus (T2DM) and the declining approval rate of new antidiabetic drugs highlight an urgent need for safer and more effective therapeutics. Partial PPARγ agonists have emerged as promising alternatives, offering efficacy with reduced side effects than full agonists. This study employed a comprehensive in silico strategy, combining ligand-based pharmacophore modeling, 3D-QSAR, ADME pre-filtering, virtual screening, molecular docking, MM-GBSA binding energy calculations, MD simulations, DFT analysis and toxicity predictions. A validated six-feature pharmacophore and robust 3D-QSAR model were developed from 71 known PPARγ agonists with reported antidiabetic activity. Virtual screening of ~ 600,000 ZINC compounds identified four promising hits, CHEMBL1825121, CHEMBL4642973, CHEMBL4569907, and CHEMBL294165. These compounds showed superior docking scores (- 10.919 to - 10.386 kcal/mol) and MM-GBSA energies (- 85.9 to - 63.96 kcal/mol) compared to the internal ligand SR145 (- 10.351 kcal/mol, - 85.63 kcal/mol) and standard drugs; rosiglitazone (- 7.272 kcal/mol, - 48.14 kcal/mol) and pioglitazone (- 7.033 kcal/mol, - 47.21 kcal/mol). Detailed docking analysis revealed key interactions with Arg288, Ser342, and Glu343, consistent with partial agonism, while avoiding strong AF-2 helix stabilization associated with full activation. MD simulations confirmed the stability of the ligand-PPARγ complexes over 500 ns, while DFT analysis revealed favorable electronic and chemical reactivity profiles. Among the four identified hits, CHEMBL1825121 and CHEMBL4569907 were identified as the top candidates, displaying strong binding affinity, high structural stability and favorable pharmacokinetic properties. While experimental validation remains essential, these findings provide a rational strategy for the development of next-generation PPARγ modulators for T2DM.
Indexed as
Identifiers
41251882What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.